A case of pelvic squamous cell carcinoma of unknown primary origin that responded well to radiotherapy and nivolumab
Squamous cell carcinoma of unknown primary origin in the pelvis is rare. We report a case of a 64-year-old woman with a large osteolytic squamous cell carcinoma of unknown primary origin in the pelvis that presented with p16 expression. The patient presented with leg pain and swelling and was admitt...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-05-01
|
| Series: | Radiology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1930043324000591 |
| _version_ | 1797267219605880832 |
|---|---|
| author | Hiroaki Koge, MD Ayako Hino, MD, PhD Akira Kakiuchi, MD Yayoi Yamamoto, MD, PhD Akira Kanbe, MD Daichi Kojima, MD Ayumi Horikawa, MD, PhD Tsunehiro Doiuchi, MD Hiroaki Kurihara, MD, PhD |
| author_facet | Hiroaki Koge, MD Ayako Hino, MD, PhD Akira Kakiuchi, MD Yayoi Yamamoto, MD, PhD Akira Kanbe, MD Daichi Kojima, MD Ayumi Horikawa, MD, PhD Tsunehiro Doiuchi, MD Hiroaki Kurihara, MD, PhD |
| author_sort | Hiroaki Koge, MD |
| collection | DOAJ |
| description | Squamous cell carcinoma of unknown primary origin in the pelvis is rare. We report a case of a 64-year-old woman with a large osteolytic squamous cell carcinoma of unknown primary origin in the pelvis that presented with p16 expression. The patient presented with leg pain and swelling and was admitted to our hospital. Computed tomography scans of the pelvis revealed a large osteolytic tumor. A computed tomography-guided needle biopsy was performed, and pathological examination revealed neoplastic cells with metastatic squamous cell carcinoma presenting with p16 expression. Despite a whole-body examination, tumor origin remained undetected. The patient was treated for this metastatic squamous cell carcinoma of unknown primary using palliative radiotherapy for hip pain and nivolumab. Remarkable reduction in the tumor marker levels and tumor size were obtained after therapy. Finally, partial remission and progression-free survival for more than 7 months were achieved. In conclusion, we experienced a rare case with a large p16-positive squamous cell carcinoma of unknown primary in pelvis, which responded well to radiotherapy and nivolumab. |
| first_indexed | 2024-03-07T21:53:47Z |
| format | Article |
| id | doaj.art-e5fe860a1fed46678746c4e12db02619 |
| institution | Directory Open Access Journal |
| issn | 1930-0433 |
| language | English |
| last_indexed | 2024-04-25T01:13:07Z |
| publishDate | 2024-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Radiology Case Reports |
| spelling | doaj.art-e5fe860a1fed46678746c4e12db026192024-03-10T05:11:44ZengElsevierRadiology Case Reports1930-04332024-05-0119518811885A case of pelvic squamous cell carcinoma of unknown primary origin that responded well to radiotherapy and nivolumabHiroaki Koge, MD0Ayako Hino, MD, PhD1Akira Kakiuchi, MD2Yayoi Yamamoto, MD, PhD3Akira Kanbe, MD4Daichi Kojima, MD5Ayumi Horikawa, MD, PhD6Tsunehiro Doiuchi, MD7Hiroaki Kurihara, MD, PhD8Department of Diagnostic and Interventional Radiology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 2410815, JapanCorresponding author.; Department of Diagnostic and Interventional Radiology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 2410815, JapanDepartment of Diagnostic and Interventional Radiology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 2410815, JapanDepartment of Diagnostic and Interventional Radiology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 2410815, JapanDepartment of Diagnostic and Interventional Radiology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 2410815, JapanDepartment of Diagnostic and Interventional Radiology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 2410815, JapanDepartment of Diagnostic and Interventional Radiology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 2410815, JapanDepartment of Diagnostic and Interventional Radiology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 2410815, JapanDepartment of Diagnostic and Interventional Radiology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 2410815, JapanSquamous cell carcinoma of unknown primary origin in the pelvis is rare. We report a case of a 64-year-old woman with a large osteolytic squamous cell carcinoma of unknown primary origin in the pelvis that presented with p16 expression. The patient presented with leg pain and swelling and was admitted to our hospital. Computed tomography scans of the pelvis revealed a large osteolytic tumor. A computed tomography-guided needle biopsy was performed, and pathological examination revealed neoplastic cells with metastatic squamous cell carcinoma presenting with p16 expression. Despite a whole-body examination, tumor origin remained undetected. The patient was treated for this metastatic squamous cell carcinoma of unknown primary using palliative radiotherapy for hip pain and nivolumab. Remarkable reduction in the tumor marker levels and tumor size were obtained after therapy. Finally, partial remission and progression-free survival for more than 7 months were achieved. In conclusion, we experienced a rare case with a large p16-positive squamous cell carcinoma of unknown primary in pelvis, which responded well to radiotherapy and nivolumab.http://www.sciencedirect.com/science/article/pii/S1930043324000591Unknown primary originPelvis, OsteolyticSquamous cell carcinomaRadiotherapyNivolumab |
| spellingShingle | Hiroaki Koge, MD Ayako Hino, MD, PhD Akira Kakiuchi, MD Yayoi Yamamoto, MD, PhD Akira Kanbe, MD Daichi Kojima, MD Ayumi Horikawa, MD, PhD Tsunehiro Doiuchi, MD Hiroaki Kurihara, MD, PhD A case of pelvic squamous cell carcinoma of unknown primary origin that responded well to radiotherapy and nivolumab Radiology Case Reports Unknown primary origin Pelvis, Osteolytic Squamous cell carcinoma Radiotherapy Nivolumab |
| title | A case of pelvic squamous cell carcinoma of unknown primary origin that responded well to radiotherapy and nivolumab |
| title_full | A case of pelvic squamous cell carcinoma of unknown primary origin that responded well to radiotherapy and nivolumab |
| title_fullStr | A case of pelvic squamous cell carcinoma of unknown primary origin that responded well to radiotherapy and nivolumab |
| title_full_unstemmed | A case of pelvic squamous cell carcinoma of unknown primary origin that responded well to radiotherapy and nivolumab |
| title_short | A case of pelvic squamous cell carcinoma of unknown primary origin that responded well to radiotherapy and nivolumab |
| title_sort | case of pelvic squamous cell carcinoma of unknown primary origin that responded well to radiotherapy and nivolumab |
| topic | Unknown primary origin Pelvis, Osteolytic Squamous cell carcinoma Radiotherapy Nivolumab |
| url | http://www.sciencedirect.com/science/article/pii/S1930043324000591 |
| work_keys_str_mv | AT hiroakikogemd acaseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT ayakohinomdphd acaseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT akirakakiuchimd acaseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT yayoiyamamotomdphd acaseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT akirakanbemd acaseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT daichikojimamd acaseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT ayumihorikawamdphd acaseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT tsunehirodoiuchimd acaseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT hiroakikuriharamdphd acaseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT hiroakikogemd caseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT ayakohinomdphd caseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT akirakakiuchimd caseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT yayoiyamamotomdphd caseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT akirakanbemd caseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT daichikojimamd caseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT ayumihorikawamdphd caseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT tsunehirodoiuchimd caseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab AT hiroakikuriharamdphd caseofpelvicsquamouscellcarcinomaofunknownprimaryoriginthatrespondedwelltoradiotherapyandnivolumab |